Why the study?
Does perioperative extended-release metoprolol succinate reduce major cardiovascular events at 30 days in patients undergoing noncardiac surgery compared with placebo?
Does perioperative extended-release metoprolol succinate reduce major cardiovascular events at 30 days in patients undergoing noncardiac surgery compared with placebo?
The POISE trial demonstrated that while perioperative metoprolol CR prevents myocardial infarction in noncardiac surgery, it significantly increases the 30-day risk of death and stroke, largely mediated by clinically significant hypotension and bradycardia.
Answers are grounded in this paper and cite their sources.
May warrant avoiding routine perioperative metoprolol; leaves open optimal beta-blocker strategies for noncardiac surgery.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Devereaux et al. (2011) conducted a review in Patients undergoing noncardiac surgery (n=8,351). Extended-release metoprolol succinate (metoprolol CR) vs. Matching placebo was evaluated on Composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac arrest at 30 days (HR 0.84, 95% CI 0.70-0.99, p=0.04).
Synapse has enriched 10 related papers. Consider them for comparative context: